An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers
Publication in refereed journal


Times Cited
Web of Science6WOS source URL (as at 29/11/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractINTRODUCTION:

Nivolumab is a programmed cell death 1 (PD-1) inhibitor that has been approved for treatment of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma and classical Hodgkin's lymphoma.

AREAS COVERED:

This review summarizes the latest evidence on nivolumab's pharmacodynamics, pharmacokinetics, safety and clinical efficacy in different solid tumors, based on published studies and abstracts from international conferences.

EXPERT OPINION:

Multiple high-level evidence has confirmed the efficacy and safety of nivolumab in solid tumors. Further studies should focus on the identification of potential predictive biomarkers and possibility of combining with other immunotherapeutic or cytotoxic agents. The optimal sequence, treatment duration and possibility of re-challenging patients who had prior nivolumab are yet to be defined.
Acceptance Date08/08/2016
All Author(s) ListAshley CY Wong, Brigette Ma
Journal nameExpert Opinion on Drug Metabolism and Toxicology
Year2016
Month10
Volume Number12
Issue Number10
PublisherLondon : Informa Healthcare
Place of PublicationEngland
Pages1255 - 1261
ISSN1742-5255
eISSN1744-7607
LanguagesEnglish-United Kingdom
KeywordsImmunotherapy, PD-1, lung cancer, melanoma, nivolumab, renal cell carcinoma

Last updated on 2020-30-11 at 01:54